European Society of Radiology

Delsym Uncovers A Simple Solution for Families this Cold & Flu Season: Convenient Comforting Meal Kits Delivered Straight to Their Door

Retrieved on: 
Wednesday, December 6, 2023
Cough, Mac, OnePoll, Market Research Society, Reckitt, European Society of Radiology, Cooking, AAPOR, Weather, Research, Rest, Marketing, Cheese, Delsym, Public opinion, ESOMAR, Parent, Family, Opinion, The New York Times

PARSIPPANY, N.J., Dec. 6, 2023 /PRNewswire/ -- If you're a parent with school-aged children, you know that as soon as one kid starts showing cough and cold symptoms, it's only a matter of time before the entire household is caught in the storm. That's why this cold and flu season, Delsym – a Reckitt brand and the #1 doctor recommended* 12-hour cough suppressant – is helping families feel better together by providing them with a cozy, convenient, and delicious comfort meal kit.

Key Points: 
  • That's why this cold and flu season, Delsym – a Reckitt brand and the #1 doctor recommended* 12-hour cough suppressant – is helping families feel better together by providing them with a cozy, convenient, and delicious comfort meal kit.
  • Most families make the best of their sick days by coming together to watch TV and cook comfort meals.
  • As part of a nationwide campaign sweepstakes, Delsym is creating exclusive meal kits featuring Anthony's favorite family soup recipe and delivering them to 250 lucky families throughout cold and flu season.
  • With a delicious and convenient chicken soup recipe kit delivered to your door, Delsym is here to help bring comfort home this season."

IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights

Retrieved on: 
Wednesday, November 15, 2023
Lung, Woman, CIRSE, Freezing, Patient, Participation, Research, Kidney, Marketing, Neoplasm, Conference, Congress, System, ICE3, Hamas, Webcast, Safety, Food, Luminate (company), European Society of Radiology, Conference call, ANVISA, Health, Breast, Cryoablation, Breast cancer, Kidney cancer, Nine Months, Classification, Brazilian Health Regulatory Agency, Prostate, Health Canada, De novo, Circulatory system, Liver, Novomer, Episcopal conference, FDA, Cancer Diagnostic Probe, Medical device, Pharmaceutical industry, Nursing, Medical imaging, Birth control, Cryptocurrency, Broadcasting, Luminal

Gross profit was $0.73 million for the nine months ended September 30, 2023, compared to $0.98 million for the nine months ended September 30, 2022.

Key Points: 
  • Gross profit was $0.73 million for the nine months ended September 30, 2023, compared to $0.98 million for the nine months ended September 30, 2022.
  • Gross margin was 37% for the nine months ended September 30, 2023, compared to 46% for the nine months ended September 30, 2022.
  • Research and development expenses for the nine months ended September 30, 2023, were $6.39 million compared to $6.89 million for the nine months ended September 30, 2022.
  • Total operating expenses for the nine months ended September 30, 2023, were $12.89 million, compared to $13.79 million for the nine months ended September 30, 2022.

Prostate Cancer Diagnosis Just Got Easier with CE Mark Certification of Lucida Medical's New AI Software

Retrieved on: 
Monday, October 23, 2023
Sale, Trial of the century, MRI, Radiology, Active surveillance of prostate cancer, CE, Certification, Entrepreneurship, Prostate cancer, Software, NHS, Life expectancy, Hospital, Biopsy, IRCCS, European Society of Radiology, Cancer, CE marking, Patient, Diagnosis, Prostate, Lancet, Medical imaging, EU

CAMBRIDGE, United Kingdom, Oct. 23, 2023 /PRNewswire/ -- Lucida Medical Ltd, a Cambridge-based start-up company dedicated to improving cancer diagnosis, has announced Class IIb CE certification for its AI-based prostate cancer detection software, Prostate Intelligence™ (Pi™).

Key Points: 
  • CAMBRIDGE, United Kingdom, Oct. 23, 2023 /PRNewswire/ -- Lucida Medical Ltd, a Cambridge-based start-up company dedicated to improving cancer diagnosis, has announced Class IIb CE certification for its AI-based prostate cancer detection software, Prostate Intelligence™ (Pi™).
  • Built with leading clinicians and UK NHS hospitals, the CE mark means the software can now benefit patients across Europe.
  • Using AI, Pi™ analyses the MRI and is fully integrated into the radiologist's workflow, targeting key issues of variability, radiologist time, and diagnostic accuracy in prostate cancer.
  • As the most common cancer in men, each year, prostate cancer gains 1.4 million diagnoses and claims 375,000 lives.

National Savings Day Survey Finds Americans Are Hopeful Their Saving Habits Will Improve This Year

Retrieved on: 
Thursday, October 12, 2023
KeyBank, Market Research Society, ESOMAR, American Association for Public Opinion Research, AAPOR, St. Louis Fed Financial Stress Index, Marketing, National Savings and Investments, Research, Opinion, OnePoll, Emergency, Public opinion, European Society of Radiology, Habit, Bank

NEW YORK, Oct. 12, 2023 /PRNewswire/ -- Amidst ongoing economic uncertainty, most people know they should be saving a portion of their income to cover unexpected expenses, mitigate financial stress and plan for a more secure future. However, according to a new National Savings Day survey released today by Laurel Road, a digital banking platform of KeyBank with specialized offerings for healthcare and business professionals, only 4 in 10 Americans could live off their cash savings for longer than four months.

Key Points: 
  • However, according to a new National Savings Day survey released today by Laurel Road, a digital banking platform of KeyBank with specialized offerings for healthcare and business professionals, only 4 in 10 Americans could live off their cash savings for longer than four months.
  • These emergencies include unexpected debt (16%), rising rent or mortgage payments (16%) and unforeseen medical bills (14%.)
  • Despite most people needing to utilize their savings to cover unexpected expenses, the majority (71%) also noted that they are satisfied with their current balance.
  • Over the last year, survey respondents reported increasing their cash savings accounts by an average of $23,474 and plan to add a similar amount in the next 12 months ($24,520).

Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81%

Retrieved on: 
Thursday, October 5, 2023
Neoplasm, Breast cancer, Breast, ICE3, Safety, Luminous red nova, Freezing, Luminal, Biopsy, Patient, Principal investigator, European Society of Radiology, PMID, Woman, Medical imaging

This independent study adds to the growing body of scientific data using ProSense in women deemed inoperable for breast cancer.

Key Points: 
  • This independent study adds to the growing body of scientific data using ProSense in women deemed inoperable for breast cancer.
  • During the study, ultrasound-guided cryoablation using ProSense was performed on 28 women, who had biopsy-proven malignant lesions, and were deemed inoperable by a multidisciplinary group, and submitted to hormone therapy.
  • At a median age of 73.4 years, 14 of the women were diagnosed with molecular subtype Luminal-A tumors and another 14 diagnosed with Luminal-B tumors.
  • Patients were monitored at one, three, and six months post-procedure, at which time the tumor size reduction rate was evaluated by ultrasound.

ScreenPoint Medical Showcases Global Momentum for Transpara(R) Breast AI at EUSOBI

Retrieved on: 
Thursday, September 28, 2023
Journal of Clinical Oncology, Risk, The, Mayo Clinic, University, American Journal of Clinical Oncology, Workflow, Breast cancer awareness, Radiology, Breast, Cancer, Risk assessment, Woman, University of California, Density, Journal, Publication, Triage, The Lancet, Breast cancer, Algorithm, Randomized controlled trial, Interval, Artificial Intelligence System, Workload, Artificial intelligence, Diagnosis, Clinical professor, European Society of Radiology, Research, AI, Mammography, Medical device, Medical imaging, European Radiology

VALENCIA, Spain, Sept. 28, 2023 /PRNewswire/ -- ScreenPoint Medical is showcasing global momentum for Transpara, the world's leading Breast artificial intelligence (AI) software, here at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting, September 28-30, 2023 (Booth M02). 

Key Points: 
  • VALENCIA, Spain, Sept. 28, 2023 /PRNewswire/ -- ScreenPoint Medical is showcasing global momentum for Transpara, the world's leading Breast artificial intelligence (AI) software, here at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting, September 28-30, 2023 (Booth M02).
  • Headlining the publications are preliminary results from the first randomized controlled trial in Breast AI: the Mammography Screening with AI (MASAI) Study published this summer in Lancet Oncology.
  • Results on prior mammograms with a Transpara score of 10 illustrate the potential for earlier detection of breast cancers by using AI in screen-reading.
  • These studies have validated Transpara's performance in helping radiologists detect cancer earlier and safely reduce workload," said Mark Koeniguer, ScreenPoint Medical CEO.

Renowned Spanish Radiologist Lucía Graña-López to Present Data Using IceCure Medical's ProSense at European Society of Breast Imaging Scientific Meeting 2023

Retrieved on: 
Friday, September 22, 2023
Neoplasm, Breast, Research, Doctor of Philosophy, MD, Freezing, Patient, European, Poster, European Society of Radiology, Malignancy, Safety, Breast cancer, Medical imaging

Dr. Grana-Lopez' poster presentation, titled "Cryoablation for the treatment of early-stage breast cancer in patients who decline surgery" will be presented at the European Society of Breast Imaging (" EUSOBI ") Scientific Meeting which will take place in Valencia, Spain from September 29-30, 2023.

Key Points: 
  • Dr. Grana-Lopez' poster presentation, titled "Cryoablation for the treatment of early-stage breast cancer in patients who decline surgery" will be presented at the European Society of Breast Imaging (" EUSOBI ") Scientific Meeting which will take place in Valencia, Spain from September 29-30, 2023.
  • ProSense and its disposable cryoprobes and introducers are used throughout Europe both directly by IceCure and through distributors in Spain, Portugal, Italy, France, Germany, the Netherlands, Poland, Hungary, and Romania.
  • Dr. Graña-López, a radiologist that specializes in breast and women's imaging uses the Company's ProSense to treat cancerous and benign breast tumors.
  • "We look forward to building more momentum with the commercialization of ProSense throughout Europe at the EUSOBI annual scientific meeting.

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Retrieved on: 
Tuesday, September 12, 2023
Karolinska Institute, Partnership, Therapy, Ramsay, Radiology, Woman, Research, CDR, Guideline, Patient, Reading, Cancer, Hospital, AI, European Society of Radiology, FDA, Breast cancer, Medical imaging

"This prospective study lays the groundwork for the widespread adoption of AI in breast cancer screening by filling the role of one radiologist, which in turn can reduce medical costs and lead to healthcare reimbursement."

Key Points: 
  • "This prospective study lays the groundwork for the widespread adoption of AI in breast cancer screening by filling the role of one radiologist, which in turn can reduce medical costs and lead to healthcare reimbursement."
  • Conducted from April 1, 2021, to June 9, 2022, this study meticulously analyzed 55,581 breast cancer screening cases in real-world clinical settings.
  • Based on the contract, Lunit has integrated Lunit INSIGHT MMG, marking the first-ever actual implementation where AI replaces one of the two human readers in breast cancer screening.
  • "This study signifies a milestone in healthcare, ushering in an era where AI seamlessly complements and elevates the standards of breast cancer screening.

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Retrieved on: 
Monday, September 11, 2023
Karolinska Institute, Partnership, Therapy, Ramsay, Radiology, Woman, Research, CDR, Guideline, Patient, Reading, Cancer, Hospital, AI, European Society of Radiology, FDA, Breast cancer, Medical device, Medical imaging

SEOUL, South Korea, Sept. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is spearheading a transformative change in breast cancer screening, bolstered by groundbreaking findings from a prospective study led by Dr. Fredrik Strand at the Karolinska Institutet, Sweden, involving over 50,000 women.

Key Points: 
  • "This prospective study lays the groundwork for the widespread adoption of AI in breast cancer screening by filling the role of one radiologist, which in turn can reduce medical costs and lead to healthcare reimbursement."
  • Conducted from April 1, 2021, to June 9, 2022, this study meticulously analyzed 55,581 breast cancer screening cases in real-world clinical settings.
  • Based on the contract, Lunit has integrated Lunit INSIGHT MMG, marking the first-ever actual implementation where AI replaces one of the two human readers in breast cancer screening.
  • "This study signifies a milestone in healthcare, ushering in an era where AI seamlessly complements and elevates the standards of breast cancer screening.

New Survey Reveals Majority of Americans Find Credit Cards Make It Challenging to Manage Their Finances

Retrieved on: 
Thursday, August 17, 2023
Technology, Payments, Finance, Fintech, Banking, Professional Services, Software, Networks, Other Professional Services, Public opinion, Opinion, Michálek, ESOMAR, Market Research Society, OnePoll, Privacy, SMS, Marketing, American Association for Public Opinion Research, Growth, European Society of Radiology, Research, AAPOR, Libor Michálek, Bank, Credit, Affirmation

Despite a majority of Americans (64%) reporting that they feel "in control of their finances," nearly eight in 10 (79%) think they could be doing a better job managing them.

Key Points: 
  • Despite a majority of Americans (64%) reporting that they feel "in control of their finances," nearly eight in 10 (79%) think they could be doing a better job managing them.
  • Americans' increased savings may help explain why more than three in four (76%) Americans feel prepared for a potential recession.
  • Americans are seeking more control and flexibility from payment options that can help them better manage their finances, the survey found.
  • This random double-opt-in survey of 2,000 general population Americans was commissioned by Affirm between June 20 and June 23, 2023.